Beta Bionics Quarterly Cash Flow Statement
NASDAQ: BBNXHealthcareMedical DevicesUSD
17.63+0.20 (+1.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beta Bionics free cash flow
In the quarter ended Jun 30, 2026, Beta Bionics generated -$14.6 million of operating cash flow and spent $1.0 million on capital expenditures. That left free cash flow of -$15.7 million, a free-cash-flow margin of -48.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Beta Bionics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -23.40M | -21.89M | -13.47M | -14.21M | -16.87M | -28.66M | -18.11M | -9.74M | -14.46M | -12.45M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 709.00K | 585.00K | 538.00K | 385.00K | 347.00K | 303.00K | 232.00K | 333.00K | 299.00K | 287.00K |
| Stock-Based Compensation | 7.02M | 5.41M | 4.30M | 4.48M | 4.80M | 2.80M | 1.55M | 1.98M | 1.50M | 1.36M |
| Change in Working Capital | 1.02M | -2.62M | -7.16M | -3.67M | -4.95M | -922.00K | -6.17M | -2.57M | -4.76M | -4.43M |
| Operating Cash Flow | -14.62M | -23.83M | -8.63M | -8.73M | -13.59M | -19.98M | -14.28M | -9.61M | -12.24M | -12.14M |
| Capital Expenditures | -1.04M | -1.38M | -1.90M | -1.28M | -1.78M | -333.00K | -561.00K | -1.92M | -507.00K | -406.00K |
| Investing Cash Flow | 26.93M | 21.84M | 658.00K | 9.49M | 6.17M | -179.12M | -29.66M | 15.24M | 3.30M | 7.64M |
| Financing Cash Flow | 1.80M | 623.00K | 1.06M | 2.65M | 42.00K | 211.12M | 56.89M | -1.18M | -107.00K | 6.00K |
| Net Change in Cash | 14.11M | -1.37M | -6.91M | 3.41M | -7.38M | 12.02M | 12.95M | 4.45M | -9.04M | -4.49M |
| Free Cash Flow | -15.66M | -25.21M | -10.53M | -10.01M | -15.37M | -20.31M | -14.84M | -11.53M | -12.74M | -12.55M |
This table shows 10 quarterly periods of Beta Bionics's cash flow statement, from Q2 2026 back to Q1 2024, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BBNX's reporting calendar. What is a cash flow statement?